Gastric Cancer
Conditions
Brief summary
To investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.
Detailed description
We will retrospectively enroll patients diagnosed with advanced or metastatic gastric cancer at the Department of Medical Oncology and Radiation Sickness of Peking University Third Hospital. The retrospective study aims to investigate the impact of bleeding on treatment-related adverse events (TRAEs) for gastric cancer patients receiving systematic anticancer treatment, assess the influence of bleeding on the survival of patients.
Interventions
All patients received systematic therapy including chemotherapy, targeted therapy or immune checkpoint inhibitor. We aims to investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.
Sponsors
Peking University Third Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
1. Patients older than 18 years; 2. A histologically confirmed diagnosis of advanced or metastatic gastric cancer; 3. The initial anticancer treatment was systematic therapy, including chemotherapy, targeted therapy or immune checkpoint inhibitor (ICI); 4. No history of gastrectomy before systematic therapy.
Exclusion criteria
1. Incompletable clinical data; 2. Siewert I type esophagus cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | from date of the first cycle of systematic therapy to death from any cause，assessed up to 120 months | OS was defined as the time from the first cycle of systematic therapy to death from any cause. |
Contacts
Primary ContactYanhong Yao
Outcome results
None listed